X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-new-drug-application-acceptance-by-singapore-health-sciences-authority-hsa-for-dextenza-for-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-and-ocular-itching-associated-wi-302064649.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-first-patient-treated-in-phase-3-registrational-clinical-trial-in-mainland-china-for-dextenza-for-the-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-301931587.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-partner-vistagen-reports-positive-top-line-results-from-phase-3-palisade-2-trial-of-fasedienol-ph94b-nasal-spray-in-social-anxiety-disorder-301897671.html
https://www.asiaone.com/business/affamed-therapeutics-announces-completion-patient-enrollment-real-world-study-china
https://www.prnewswire.com/news-releases/prof-roger-d-kornberg-chemistry-nobel-laureate-will-be-joining-tissue-dynamics-advisory-board-301838660.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-completion-of-patient-enrollment-in-the-real-world-study-in-china-evaluating-the-safety-and-efficacy-of-dextenza-in-cataract-surgery-patients-301838072.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-partner-allgenesis-reports-encouraging-preliminary-safety-and-efficacy-data-from-the-ag-73305-phase-2a-trial-for-the-treatment-of-diabetic-macular-edema-301834448.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-approval-to-initiate-a-phase-3-registrational-clinical-trial-in-mainland-china-for-dextenza-for-the-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-301797505.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-to-commercialize-galcanezumab-for-migraine-prevention-in-mainland-china-301720180.html
Market Place
Share 
